IRCT20200105046010N44招募中未知
In- Vivo Bioequivalence study of Everolimus tablet 10 & 0.75 mg SOBHAN ONCOLOGY (Everolimus 10mg) with brand drug (AFINITOR® 10mg Novartis) in Iranian healthy volunteers
SOBHAN ONCOLOGY Pharmaceutical CO.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-60 years old
排除标准
- •History of cardiovascular disease
- •History of liver or kidney disease
- •Alcohol & Drug addiction
- •History of hypersensitivity
研究者
相似试验
尚未招募
不适用
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24
招募中
不适用
Bioequivalence study of Everolimus 0.75mg tabletIRCT20200623047902N12Alborz Zagros company24
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.IRCT20200105046010N51Abidi Pharmaceutical Company24